Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a diagnosis of open angle glaucoma (OAG) (including normal-tension glaucoma \[NTG\],pigmentary or pseudoexfoliative glaucoma), or ocular hypertension (OHT) in one or both eyes.~* Subjects must meet the following IOP requirements at Visit 3 (Eligibility, Day 0\[after washout for the subjects already on treatment\]): mean/median IOP ≥15 mmHg and ≤36 mmHg at 10 AM in at least 1 eye; and IOP ≤36 mmHg in both eyes.~* Subjects with a corrected Decimal visual acuity (VA) or a Best-Corrected Decimal Visual Acuity (BCVA) of 0.5 or better in both eyes.~Exclusion Criteria:~* Subjects who are unable to discontinue contact lens use during and for 15 minutes following instillation of study drug and during study visits.~* Subjects who are unable to discontinue other eye drop medications such as artificial tears for 15 minutes prior to and 15 minutes after instillation of study drug.~* Subjects with a central corneal thickness greater than 600 μm in either eye.~* Subjects with any condition that prevents reliable applanation tonometry in either eye.~* Subjects with advanced glaucoma with a mean deviation (MD) \< -12 dB, a history of split fixation, or a field loss threatening fixation in either eye.~* Subjects with any condition that prevents clear visualization of the fundus.~* Subjects who are monocular (fellow eye is absent).~* Subjects with aphakia in either eye.~* Subjects with an active corneal disease in either eye.~* Subjects with severe dry eye in either eye.~* Subjects with a history/diagnosis of a clinically significant or progressive retinal disease in either eye.~* Subjects with very narrow angles and subjects with angle closure congenital, or secondary glaucoma, and subjects with history of angle closure in either eye.~* Subjects with any intraocular infection or inflammation in either eye within 3 months prior to Visit 1 (Screening).~* Subjects with a history of ocular laser surgery in either eye within the 3 months (90 days) prior to Visit 1 (Screening).~* Subjects with a history of incisional ocular surgery or severe trauma in either eye within 3 months prior to Visit 1 (Screening).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Latanoprostene Bunod (Type: EXPERIMENTAL): Latanoprostene bunod 0.024% instilled into the eye once daily (QD) over a 1-year treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).